Kilele Health Announces Global First in Wearable Sensors

Dayton/Cincinnati, OH – March 23, 2025

Kilele Health Inc.™ (“Kilele”) announced it has demonstrated in vivo 10-day performance of its SunVida™ wearable aptamer biosensor. This is believed to be the first demonstration of 10-day sensor life in a mammalian model for any aptamer biosensor technology in the world.

The study, conducted in a porcine animal model, measured a key hormone biomarker with no significant decline in performance over the 10-day period. Dr. Jason Heikenfeld, Kilele CTO, explained “This is a major commercial proof point for our proprietary technology and validates the many pending early patents protecting this innovation. This critical milestone brings our dream of a wearable that provides real-time and predictive health insights based on measuring blood biomarkers that much closer to reality.”

The work leading to this seminal achievement has been supported by the National Science Foundation, the National Institutes of Health, and corporate collaborators. “We are very grateful for the support we have and continue to receive from both government and industry,” said Andrew Cothrel, Kilele CEO. “To tackle such a monumental challenge required a team effort, and now we are one giant step closer to reshaping how chronic diseases are managed.”

Millions of Americans suffer from chronic diseases such as heart failure, kidney disease, and diabetes, and these types of chronic conditions consume up to 85% of the money spent on healthcare each year in the U.S. The ability of Kilele’s SunVida system to provide real-time actionable information based on levels of key blood biomarkers is expected to improve patient outcomes and to save the healthcare system billions of dollars each year.

About Kilele:

Kilele is a privately held pre-market medical wearables company developing a novel platform capable of monitoring multiple blood biomarkers to provide novel insights to patients and care teams. The intention is to prevent patients from reaching a crisis state and shift care from the ER and hospital to the home and clinic. Kilele is preparing for human studies with a focus on heart failure, pediatric phenylketonuria, and patients who suffer from multiple chronic diseases.

Investor Relations & Media Inquiries

information@kilelehealth.com

Forward-looking statement

Certain statements in this release may constitute “forward-looking statements.” When used in this release, words like “may,” “will,” “can,” “should,” “expect,” “anticipate,” “believe,” “project,” or “intend” and other similar expressions are intended to identify forward-looking statements. Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.